Corporate Information
History
Corporate history
History of the company from its inception to its establishment
1988
April
Yutaka Mizushima establishes LTT Research Institute, Inc. to support research and development of DDS (Drug Delivery System) related technologies.
June
GREEN CROSS CORPORATION (currently Mitsubishi Tanabe Pharma Corporation) begins marketing a DDS formulation (liposteroid: trade name/Rimetasone®).
July
DDS formulation (liposteroid: product name: Haloart®, Haloart® S) is launched by Taiho Pharmaceutical Co.
October
TAISHO PHARMACEUTICAL HOLDINGS CO., LTD. begins marketing a DDS formulation (Lipo-PGE1: trade name/PALUX® Injection)
November
GREEN CROSS CORPORATION (currently Mitsubishi Tanabe Pharma Corporation) begins marketing a DDS formulation (Lipo-PGE1: trade name: Lipul® Injection).
Began joint research with St. Marianna University School of Medicine
Yutaka Mizushima receives the Pharmaceutical Technology Award from the Pharmaceutical Society of Japan for the invention and development of the Lipo formulation.
Began joint research with St. Marianna University School of Medicine
Yutaka Mizushima receives the Pharmaceutical Technology Award from the Pharmaceutical Society of Japan for the invention and development of the Lipo formulation.
1990
October
St. Marianna University School of Medicine Research Center for Intractable Diseases is established under the leadership of Yutaka Mizushima (first director: Yutaka Mizushima)
1992
June
KAKEN PHARMACEUTICAL CO.,LTD. launches DDS formulation (non-steroidal lipo formulation: trade name/Ropion®).
1995
March
Established currently Beijing Tide Pharmaceutical Co., Ltd., a joint venture with China-Japan Friendship Hospital (Beijing, China), and started the production and development of DDS (Lipo-PGE1: product name/Kaishi) in China with technical support from TAISHO PHARMACEUTICAL HOLDINGS CO., LTD.
1997
September
Began marketing a DDS formulation (Lipo-PGE1: trade name/Kaishi) from Beijing Tide Pharmaceutical Co., Ltd.
1998
September
TAIHO PHARMACEUTICAL CO., LTD. begins marketing a DDS formulation (liposteroid: trade name/Farnesone).
Currently Dainippon Sumitomo Pharma Co., Ltd. begins marketing a DDS formulation (liposteroid: brand name/farnelate).
Currently Dainippon Sumitomo Pharma Co., Ltd. begins marketing a DDS formulation (liposteroid: brand name/farnelate).
2001
September
Yutaka Mizushima receives the “Chinese Government Friendship Award” for the development of lipo drugs in China.
History of the Company from its establishment to the present
2003
January
LTT Laboratories, Inc. is split off and LTT Biopharma Co., Ltd. is established to take over the pharmaceutical business.
2004
October
Began marketing DDS formulation (non-steroidal lipo formulation: trade name/Kaifeng) from Beijing Tide Pharmaceutical Co., Ltd.
November
Listed on the Tokyo Stock Exchange Mothers
2005
June
Launch of Obagi Perfect Lift AA using our DDS technology by ROHTO Pharmaceutical Co., Ltd.
October
（ソーレ株式会社 (wholly owned subsidiary) is established. Entered the dispensing pharmacy business.
2006
March
Phase III clinical trial of DDS formulation AS-013 completed in the U.S.
April
Drug Discovery Research Center, Faculty of Pharmaceutical Sciences, Kumamoto University, established under the leadership of Tohru Mizushima (Professor, Kumamoto University) (First Director: Tohru Mizushima)
We have established a new endowed chair (Advanced DDS) at that Center.
We have established a new endowed chair (Advanced DDS) at that Center.
June
Concluded a joint venture agreement with Machine Parts Co., Ltd. to manufacture and sell MH-treated tableting punches.
November
Early phase II clinical trial of DDS formulation PC-SOD (injection) in Japan is completed. Efficacy confirmed in ulcerative colitis.
2007
August
PC-SOD license agreement for the whole of China was concluded with Beijing Tide Pharmaceutical Co., Ltd.
September
ASKLEPIOS Co., Ltd. becomes a wholly owned subsidiary through a share exchange
2008
March
Subsidiary ASKLEPIOS Co., Ltd. files for bankruptcy. It was excluded from the scope of consolidation.
May
Founder Yutaka Mizushima dies of acute heart failure
June
DDS formulation PC-SOD (injection) completes early phase II clinical trials in Japan, confirming efficacy in idiopathic interstitial pneumonia.
June
Tohru Mizushima becomes the second Chairman of the Board of Directors.
October
マシンパーツ販売（株）(wholly owned subsidiary) is established for the purpose of selling EIP products.
2009
February
Head office relocated to Kaigan, Minato-ku, Tokyo (Shiodome Building)
February
Transferred all shares of subsidiary ソーレ株式会社 and the company is excluded from the scope of consolidation.
April
Capital and business alliance agreement signed with Beijing Tide Pharmaceutical Co., Ltd.
August
Development of PC-SOD inhalation formulation for practical use” was selected as a grant project by New Energy and Industrial Technology Development Organization (NEDO).
September
Concluded a license agreement with Beijing Tide Pharmaceutical Co., Ltd. for the entire whole of China.
December
PC-SOD (inhalation formulation) toxicity study for practical application development started.
2010
January
Signed a joint research and development agreement with ASAHI KASEI PHARMA CORPORATION for stealth-type nanoparticles and started basic research.
May
Obtained composition (substance) patent for DDS formulation PC-SOD in the U.S.
June
DDS formulation PC-SOD is designated as an Orphan Drug by the Ministry of Health, Labour and Welfare.
July
Development of stealth-type nanoparticle PGE1 formulation for practical use” was selected as a grant project by the New Energy and Technology Development Organization (NEDO).
September
Started Phase I clinical trials of PC-SOD (inhalation formulation)
November
Signed a joint research and development agreement on stealth-type nanoparticles with Beijing Tide Pharmaceutical Co., Ltd.
December
Phase I clinical trial of PC-SOD (inhalation formulation) in repeated dosing in healthy subjects begins.
2011
March
Terminated sales activities of the Company’s EIP business
March
Tohru Mizushima receives “The Pharmaceutical Society of Japan Award for the Promotion of Science” for his drug repositioning (DR) research
April
Company’s stock is designated as Securities Under Supervision (as of April 1).
July
Company’s shares designated as Securities to Be Delisted (as of July 8)
July
Concluded a license agreement with ChongKunDang Pharm.Corp (CKD) for PC-SOD (inhalation formulation) for the whole of Korea.
August
Delisted from the Mothers market of the Tokyo Stock Exchange (as of August 9).
2012
February
Changed capital to 100 million yen (as of February 10)
Liquidated and excluded from consolidation マシンパーツ販売
Completed Phase I clinical trials of PC-SOD (inhalation formulation)
Liquidated and excluded from consolidation マシンパーツ販売
Completed Phase I clinical trials of PC-SOD (inhalation formulation)
July
Phase II international clinical trial of PC-SOD (inhalation formulation)
2013
July
Tohru Mizushima receives the Nagai Award from the Japanese DDS Society for his PC-SOD research.
2014
September
Completed Phase II clinical trials of PC-SOD (inhalation formulation)
2015
May
Tohru Mizushima receives the KIHARA Memorial Yokohama Foundation for the Advancement of Life Sciences Applied Science Award for his drug repositioning (DR) research.
June
Beijing Tide Pharmaceutical Co., Ltd. approved to conduct Phase I and II clinical trials of PC-SOD in China.
October
Signed a license agreement with currently EA Pharma Co., Ltd. for our pipeline (LT-4004).
2016
April
Established an endowed research division (Department of Advanced Drug Discovery Science) at St. Marianna University School of Medicine
May
Early Phase II clinical trials for dry eye treatment (LT-4002) begin.
2017
April
Completed early phase II clinical trials for dry eye drug (LT-4002)
2018
March
Signed a basic agreement with Nobelpharma Co., Ltd. for joint development of drug repositioning (DR) to expand the indications for existing drugs.
2019
February
Newly established our research center in Shonan Health Innovation Park (Shonan Health Innovation Park (Shonan iPark) (Shonan Research Center)
April
Commenced late stage Phase II clinical trials for dry eye treatment (LT-4002)
Commenced Phase II clinical trials (first indication) of co-development product (LT-5001) with Nobelpharma Co., Ltd.
Commenced Phase II clinical trials (first indication) of co-development product (LT-5001) with Nobelpharma Co., Ltd.
November
Commenced Phase II clinical trials (second indication) of co-development product (LT-5001) with Nobelpharma Co., Ltd.
2020
March
Signed a joint research agreement with a Japanese pharmaceutical company for the development of PC-SOD.
August
Completed late stage Phase II clinical trials for dry eye treatment (LT-4002)
December
Completed Phase II clinical trials (first indication) of a product (LT-5001) co-developed with Nobelpharma Co., Ltd.
2021
January
Commencement of tender offer by Sino Biopharmaceutical Co., Ltd.
March
Entered into a basic capital and business alliance agreement with Sino Biopharmaceutical Co., Ltd.
April
Concluded a consulting service agreement on DR with ASKA Pharmaceutical Holdings Co., Ltd.
May
Concluded an agreement with a brokerage firm for re-listing.
June
Completed Phase II clinical trials (second indication) of a product (LT-5001) co-developed with Nobelpharma Co., Ltd.
October
Confirmation of efficacy of co-development product (LT-5001) with Nobelpharma Co., Ltd.in Phase II clinical trials (second indication)
2022
January
Start of early phase II clinical trials for CIPN prophylaxis (PC-SOD)
April
Entered into a contract agreement with a major Japanese pharmaceutical company for the development of a DDS drug product.
September
Commencement of Phase III clinical trials (second indication) of a product (LT-5001) co-developed with Nobelpharma Co., Ltd.
December
Signed a business alliance agreement with Sino Biopharmaceutical Co., Ltd.
